1. Home
  2. CBIO vs AII Comparison

CBIO vs AII Comparison

Compare CBIO & AII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBIO
  • AII
  • Stock Information
  • Founded
  • CBIO 2003
  • AII 2006
  • Country
  • CBIO United States
  • AII United States
  • Employees
  • CBIO N/A
  • AII N/A
  • Industry
  • CBIO
  • AII Property-Casualty Insurers
  • Sector
  • CBIO
  • AII Finance
  • Exchange
  • CBIO Nasdaq
  • AII Nasdaq
  • Market Cap
  • CBIO 308.0M
  • AII 370.5M
  • IPO Year
  • CBIO N/A
  • AII 2025
  • Fundamental
  • Price
  • CBIO $14.29
  • AII $19.96
  • Analyst Decision
  • CBIO Strong Buy
  • AII Buy
  • Analyst Count
  • CBIO 5
  • AII 4
  • Target Price
  • CBIO $25.60
  • AII $21.67
  • AVG Volume (30 Days)
  • CBIO 98.3K
  • AII 78.8K
  • Earning Date
  • CBIO 07-31-2025
  • AII 08-12-2025
  • Dividend Yield
  • CBIO N/A
  • AII N/A
  • EPS Growth
  • CBIO N/A
  • AII N/A
  • EPS
  • CBIO N/A
  • AII 60.71
  • Revenue
  • CBIO N/A
  • AII $260,047,000.00
  • Revenue This Year
  • CBIO N/A
  • AII $25.82
  • Revenue Next Year
  • CBIO N/A
  • AII $25.78
  • P/E Ratio
  • CBIO N/A
  • AII $0.33
  • Revenue Growth
  • CBIO N/A
  • AII 1.73
  • 52 Week Low
  • CBIO $10.83
  • AII $15.78
  • 52 Week High
  • CBIO $21.40
  • AII $20.32
  • Technical
  • Relative Strength Index (RSI)
  • CBIO 52.92
  • AII N/A
  • Support Level
  • CBIO $13.50
  • AII N/A
  • Resistance Level
  • CBIO $16.00
  • AII N/A
  • Average True Range (ATR)
  • CBIO 0.79
  • AII 0.00
  • MACD
  • CBIO 0.16
  • AII 0.00
  • Stochastic Oscillator
  • CBIO 39.68
  • AII 0.00

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About AII American Integrity Insurance Group Inc. Common Stock

American Integrity Insurance Group Inc is engaged in the property and casualty insurance business. It provides personal residential property insurance for single-family homeowners and condominium owners as well as coverage for vacant dwellings and investment properties, predominantly in Florida. The Company's property and casualty insurance is currently offered in Florida, South Carolina, and Georgia.

Share on Social Networks: